spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  ORADUR 

 HSMN NewsFeed - 2 Oct 2019
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR(R) for the Treatment of Post-Surgical Pain
Biopharmaceuticals Drug Delivery Surgery FDA
 HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jun 2019
DURECT Announces $15 Million Registered Direct Offering
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 25 Apr 2019
DURECT Appoints Two New Board Members
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 19 Dec 2018
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 9 May 2018
DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR(R) (SABER(R)-Bupivacaine)
Biopharmaceuticals Drug Delivery Surgery Licensing
 HSMN NewsFeed - 20 Sep 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2017
DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR(R)
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2014
Impax and DURECT Sign a $63 Million Agreement to Develop and Commercialize DURECT’s ELADUR(R) Pain Patch
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 22 Oct 2013
Pfizer Proceeding with REMOXY(R) Development
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 27 Jan 2011
REMOXY New Drug Application Accepted by FDA
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 19 Jan 2010
DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2009
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
Biopharmaceuticals
 HSMN NewsFeed - 19 Aug 2008
Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland
Biopharmaceuticals
 HSMN NewsFeed - 10 Jun 2008
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2007
Remoxy Meets Primary Endpoint in Pivotal Phase III Study
Biopharmaceuticals
 HSMN NewsFeed - 11 Jul 2007
Patient Recruitment Completed for Pivotal Phase III Study of Remoxy
Biopharmaceuticals Pain Management
 HSMN NewsFeed - 5 May 2006
ORADUR(TM) Technology Milestone: Remoxy(TM) (ORADUR-Based Oxycodone) Commences Pivotal Phase III Program
Biopharmaceuticals
 HSMN NewsFeed - 17 Feb 2006
ORADUR(TM) Technology Milestone: Remoxy(TM) (ORADUR-based oxycodone) Receives Special Protocol Assessment and Commences Pivotal Phase III
Biopharmaceuticals Drug Delivery FDA
Return to NewsFeed  

 Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 18 additional stories matching:
ORADUR
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.